REG - hVIVO plc - Exercise of Share Options

hVIVOAnnouncement

18/09/2018 07:05

RNS Number : 0431B
hVIVO plc
18 September 2018
 


HVIVO PLC
("hVIVO" or the "Company")
 
Exercise of Share Options
 
London, UK, 18 September 2018: hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development services business, announces that, following the exercise of employee share options, application has been made to AIM for the admission of 1,366,320 new ordinary shares of 5.0p each (the "New Ordinary Shares").
 
Admission to trading on AIM of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 21 September 2018.
 
Following Admission, the total number of ordinary shares with voting rights in issue will be 80,575,074 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
 
For further information please contact:
 




hVIVO plc


 




Trevor Phillips (Executive Chairman)


+44 207 756 1300




Fleur Wood (EVP, IR & Comms)
 


 




Numis Securities Limited


 +44 207 260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)


 




James Black / Michael Burke (Corporate Broking)


 




 


 




FTI Consulting


 




Simon Conway / Victoria Foster Mitchell


+44 203 727 1000




 
 
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOELFFIIARIDLIT